Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on February 16, 2016, announcing significant amendments to its corporate bylaws, effective February 12, 2016. The most impactful change for investors is the adoption of a proxy access right for stockholders. This new provision allows eligible stockholders to nominate director candidates and include them in the company's proxy materials for future shareholder meetings. The proxy access right requires a minimum ownership stake of 3% of outstanding common stock held continuously for at least three years by a single stockholder or a group of up to 20 stockholders. These eligible stockholders can nominate up to 20% of the board or two individuals, whichever is greater, provided they meet the detailed requirements outlined in the amended bylaws. This change is intended to enhance shareholder engagement and governance, with the proxy access right becoming available for the 2017 annual meeting.
Key Highlights
- 1BMY has adopted amended bylaws, effective February 12, 2016, introducing a proxy access right for stockholders.
- 2Stockholders owning at least 3% of outstanding common stock for at least three years can nominate director candidates.
- 3A group of up to 20 stockholders can collectively meet the 3% ownership requirement.
- 4Eligible stockholders can nominate up to 20% of the Board of Directors or two individuals, whichever is greater.
- 5The proxy access right will be effective for the Company's 2017 annual meeting.
- 6The bylaws were also updated for clarifications and refinements to the advance notice bylaw for nominations and other technical changes.